tiprankstipranks
Advertisement
Advertisement

CLLS Stock Latest News

Cellectis reports Q2 adjusted EPS (35c) vs (40c) last year
The FlyCellectis reports Q2 adjusted EPS (35c) vs (40c) last year
15d ago
CLLS
CLLS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
CLLS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
18d ago
CLLS
Citizens biotech analyst holds an analyst/industry conference call
PremiumThe Fly
Citizens biotech analyst holds an analyst/industry conference call
2M ago
ALLO
CLLS
Citizens biotech analysts hold an analyst/industry conference call
PremiumThe Fly
Citizens biotech analysts hold an analyst/industry conference call
2M ago
ALLO
CLLS
Cellectis Shareholders Approve 2025 Accounts and Expand Capital-Raising Powers at June 25 Meeting
PremiumCompany Announcements
Cellectis Shareholders Approve 2025 Accounts and Expand Capital-Raising Powers at June 25 Meeting
2M ago
6K
CLLS
Cellectis Shareholders Approve Board-Backed Resolutions at June 25, 2026 Meeting
PremiumCompany AnnouncementsCellectis Shareholders Approve Board-Backed Resolutions at June 25, 2026 Meeting
2M ago
6K
CLLS
Cellectis Unveils Strong Early CAR-T Data for Lasme-cel and Eti-cel at EHA 2026
Premium
Company Announcements
Cellectis Unveils Strong Early CAR-T Data for Lasme-cel and Eti-cel at EHA 2026
2M ago
6K
CLLS
Cellectis Gains FDA RMAT Status for Allogeneic CAR-T lasme-cel in r/r B-ALL
Premium
Company Announcements
Cellectis Gains FDA RMAT Status for Allogeneic CAR-T lasme-cel in r/r B-ALL
2M ago
6K
CLLS
Cellectis granted RMAT designation for lasmecabtagene timgedleucel from FDA
PremiumThe Fly
Cellectis granted RMAT designation for lasmecabtagene timgedleucel from FDA
2M ago
CLLS
Cellectis initiated with an Overweight at Barclays
PremiumThe Fly
Cellectis initiated with an Overweight at Barclays
3M ago
CLLS
Cellectis Calls June 25, 2026 Shareholders’ Meeting to Approve 2025 Results and Broad Capital-Issuance Powers
PremiumCompany Announcements
Cellectis Calls June 25, 2026 Shareholders’ Meeting to Approve 2025 Results and Broad Capital-Issuance Powers
3M ago
6K
CLLS
Cellectis Sets June 25, 2026 Date for Annual Shareholders Meeting in Paris
PremiumCompany Announcements
Cellectis Sets June 25, 2026 Date for Annual Shareholders Meeting in Paris
3M ago
6K
CLLS
Cellectis to present clinical data on lasme-cel, eti-cel at EHA Congress
PremiumThe FlyCellectis to present clinical data on lasme-cel, eti-cel at EHA Congress
3M ago
CLLS
Cellectis to Unveil Key Lasme-cel and Eti-cel Data at EHA 2026
Premium
Company Announcements
Cellectis to Unveil Key Lasme-cel and Eti-cel Data at EHA 2026
3M ago
6K
CLLS
Cellectis reports Q1 adjusted EPS (16c) vs. (17c) last year
Premium
The Fly
Cellectis reports Q1 adjusted EPS (16c) vs. (17c) last year
3M ago
CLLS
Cellectis sees cash runway into 4Q27
PremiumThe Fly
Cellectis sees cash runway into 4Q27
3M ago
CLLS
Cellectis Files Q1 2026 Interim Financials with U.S. SEC
PremiumCompany Announcements
Cellectis Files Q1 2026 Interim Financials with U.S. SEC
3M ago
6K
CLLS
Cellectis Q1 2026 Results Highlight CAR-T Pipeline Milestones, New Epigenetic Platform and Licensing Dispute
PremiumCompany Announcements
Cellectis Q1 2026 Results Highlight CAR-T Pipeline Milestones, New Epigenetic Platform and Licensing Dispute
3M ago
6K
CLLS
CLLS Earnings this Week: How Will it Perform?
PremiumPre-Earnings
CLLS Earnings this Week: How Will it Perform?
3M ago
CLLS
Cellectis to Release First-Quarter 2026 Results on May 11
PremiumCompany AnnouncementsCellectis to Release First-Quarter 2026 Results on May 11
4M ago
6K
CLLS
Cellectis Showcases Safer Epigenetic Gene-Silencing Platform Ahead of ASGCT 2026
Premium
Company Announcements
Cellectis Showcases Safer Epigenetic Gene-Silencing Platform Ahead of ASGCT 2026
4M ago
6K
CLLS
Cellectis Highlights Positive Pivotal Interim Data for Allogeneic CAR-T Partnered Cema-cel
Premium
Company Announcements
Cellectis Highlights Positive Pivotal Interim Data for Allogeneic CAR-T Partnered Cema-cel
4M ago
6K
CLLS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >